LinkedIn
WebsiteIntroduction
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), formerly known as MyMD Pharmaceuticals, is a clinical-stage biopharmaceutical company headquartered in Baltimore, Maryland. The company focuses on developing orally dosed therapies that target tumor necrosis factor-alpha (TNF-α) to regulate the immuno-metabolic system, with applications in age-related disorders, autoimmune diseases, and chronic inflammation.
Corporate Structure
According to its LinkedIn profile, TNF Pharmaceuticals employs between 11 and 50 individuals, indicating a lean organizational model that supports agile decision-making. Leadership includes President and Chief Medical Officer Mitchell Glass, M.D., overseeing clinical strategy and development. The company operates two main research platforms:
- Isomyosamine (MYMD-1®): A small-molecule TNF-α inhibitor currently in clinical development.
- Supera-CBD: A synthetic derivative of cannabidiol targeting chronic pain, addiction, and epilepsy.
TNF inhibitors by Thought Catalog
Recent Developments and News
On July 24, 2024, the company completed its rebranding from MyMD Pharmaceuticals to TNF Pharmaceuticals, Inc. and began trading under the ticker TNFA on the Nasdaq Capital Market. In that release, management outlined plans for mid-stage clinical trials of MYMD-1® following statistically significant Phase 2 results in the treatment of sarcopenia.
In a subsequent release, TNF Pharmaceuticals entered a collaborative agreement with Renova Health to conduct a fully funded trial evaluating MYMD-1® in patients taking GLP-1 receptor agonists (e.g., Wegovy, Ozempic) who are experiencing muscle loss associated with inflammation. This study will utilize AI and machine-learning tools to identify an optimal patient cohort.
The company has also completed an FDA-recommended safety study for isomyosamine, demonstrating clinical safety over a 13-week period at multiple dose levels. Based on those findings, TNF Pharmaceuticals plans to initiate a Phase 2b trial in sarcopenia in the first quarter of 2025.
On September 2, 2025, the board approved a 1-for-100 reverse stock split to comply with Nasdaq listing standards. At the effective time, every 100 pre-split shares were combined into one post-split share, reducing the outstanding share count from 178,615,658 to 1,786,157.
Financial and Strategic Aspects
| Ticker | Price (USD) | Change (%) | Volume | Exchange |
|---|---|---|---|---|
| TNFA | 5.81 | +65.53 | 3,105,042 | NAS |
- The stock closed at USD 5.81 on September 24, 2025, reflecting a 65.53% gain for the trading session on volume of 3.1 million shares.
- Market capitalization is approximately USD 6.9 million (intraday figure).
- The reverse split is intended to restore compliance with Nasdaq’s minimum bid-price requirement.
- The strategic focus remains on advancing MYMD-1® through mid-stage trials while expanding the pipeline via Supera-CBD.
Market Position and Industry Context
- The global TNF inhibitor market was valued at USD 39.7 billion in 2024 and is projected to reach USD 47.3 billion by 2029 (CAGR 3.6%).
- The GLP-1 agonist segment, valued at USD 49.3 billion in 2024, is expected to exceed USD 105 billion by 2029 (CAGR 19.2%). Interest in GLP-1 therapies has created a demand for complementary treatments that preserve lean muscle mass.
- The sarcopenia treatment market is estimated at USD 3.07 billion in 2024 and is forecast to grow to USD 4.02 billion by 2029 (CAGR 4.48%). TNF Pharmaceuticals aims to address this need with an oral TNF-α inhibitor that can be dose-adjusted both acutely and chronically.
tl;dr
Following its rebranding effective July 24, 2024, and Nasdaq symbol change to TNFA, the company announced a collaboration with Renova Health to study its lead candidate, isomyosamine, in GLP-1–induced sarcopenia. An FDA-recommended safety study has cleared the way for a Phase 2b sarcopenia trial set for Q1 2025. On September 2, 2025, TNF executed a 1-for-100 reverse stock split to meet Nasdaq bid-price requirements. Shares closed at USD 5.81 (+65.53%) on September 24, 2025, with upcoming milestones including mid-stage trial initiations and data readouts for MYMD-1®.
